The B-cell-autoantibody axis in lung cancer immunity - PubMed
4 days ago
- #lung cancer immunotherapy
- #B-cell biology
- #tumor microenvironment
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality, with immune checkpoint inhibitor (ICI) resistance being a major challenge.
- Tumor-infiltrating B lymphocytes (TIL-Bs) and tertiary lymphoid structures (TLSs) are crucial prognostic factors in NSCLC, but their mechanistic roles are not fully understood.
- Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics reveal the dynamic roles of B-cell subsets, influenced by TLS maturation status.
- B-cells can switch between anti-tumor (e.g., antibody-secreting plasma cells) and pro-tumor (e.g., IL-10+ regulatory B cells) phenotypes.
- Autoantibodies act not just as biomarkers but also actively regulate the tumor immune microenvironment (TIME) via complement activation and ADCC.
- Targeting the B-cell-autoantibody axis offers potential clinical strategies, including B-cell-based vaccines and TLS modulation, to overcome ICI resistance.
- This review outlines a roadmap for incorporating B-cell biology into personalized immunotherapy for NSCLC.